1 |
Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002
DOI
|
2 |
Nacif MS, Arai AE, Lima JA, Bluemke DA. Gadoliniumenhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson 2012;14:18
|
3 |
Kramer U, Fenchel M, Laub G, Seeger A, Klumpp B, Bretschneider C, et al. Low-dose, time-resolved, contrastenhanced 3D MR angiography in the assessment of the abdominal aorta and its major branches at 3 Tesla. Acad Radiol 2010;17:564-576
DOI
|
4 |
Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576
DOI
|
5 |
Ishiguchi T, Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 2010;10:133-145
DOI
|
6 |
Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, et al. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 2013;23:1250-1259
DOI
|
7 |
Wagner M, Schilling R, Doeblin P, Huppertz A, Luhur R, Schwenke C, et al. Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine. Eur Radiol 2013;23:108-114
DOI
|
8 |
Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-790
DOI
|
9 |
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174
DOI
|
10 |
Cheng AS, Robson MD, Neubauer S, Selvanayagam JB. Irreversible myocardial injury: assessment with cardiovascular delayed-enhancement MR imaging and comparison of 1.5 and 3.0 T--initial experience. Radiology 2007;242:735-742
DOI
|
11 |
Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007;7:130-137
DOI
|
12 |
Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 2003;5:505-514
DOI
|
13 |
Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-1453
DOI
|
14 |
Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 2006;7:237-247
DOI
|
15 |
Haacke EM, Brown RW, Thompson MR, Venkatesan R. Magnetic resonance imaging: physical principles and sequence design, 1st ed. New Jersey: John Wiley & Sons, 1999
|
16 |
Farrelly C, Rehwald W, Salerno M, Davarpanah A, Keeling AN, Jacobson JT, et al. Improved detection of subendocardial hyperenhancement in myocardial infarction using dark blood-pool delayed enhancement MRI. AJR Am J Roentgenol 2011;196:339-348
DOI
|
17 |
Wieben O, Francois C, Reeder SB. Cardiac MRI of ischemic heart disease at 3 T: potential and challenges. Eur J Radiol 2008;65:15-28
DOI
|
18 |
Klumpp B, Fenchel M, Hoevelborn T, Helber U, Scheule A, Claussen C, et al. Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla. Invest Radiol 2006;41:661-667
DOI
|
19 |
Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 1984;11:425-448
DOI
|
20 |
Kim YK, Park EA, Lee W, Kim SY, Chung JW. Late gadolinium enhancement magnetic resonance imaging for the assessment of myocardial infarction: comparison of image quality between single and double doses of contrast agents. Int J Cardiovasc Imaging 2014;30 Suppl 2:129-135
|
21 |
Kim HW, Rehwald WG, Wendell DC, Jenista E, Assche LV, Jensen CJ, et al. Flow-Independent Dark-blood DeLayed Enhancement (FIDDLE): validation of a novel black blood technique for the diagnosis of myocardial infarction. J Cardiovasc Magn Reson 2016;18(Suppl 1):O55
DOI
|
22 |
Peel SA, Morton G, Chiribiri A, Schuster A, Nagel E, Botnar RM. Dual inversion-recovery mr imaging sequence for reduced blood signal on late gadolinium-enhanced images of myocardial scar. Radiology 2012;264:242-249
DOI
|
23 |
Secchi F, Di Leo G, Papini GD, Giacomazzi F, Di Donato M, Sardanelli F. Optimizing dose and administration regimen of a high-relaxivity contrast agent for myocardial MRI late gadolinium enhancement. Eur J Radiol 2011;80:96-102
DOI
|
24 |
De Cobelli F, Esposito A, Perseghin G, Sallemi C, Belloni E, Ravelli S, et al. Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI. AJR Am J Roentgenol 2012;198:809-816
DOI
|
25 |
Herborn CU, Runge VM, Watkins DM, Gendron JM, Naul LG. MR angiography of the renal arteries: intraindividual comparison of double-dose contrast enhancement at 1.5 T with standard dose at 3 T. AJR Am J Roentgenol 2008;190:173-177
DOI
|
26 |
Fratz S, Chung T, Greil GF, Samyn MM, Taylor AM, Valsangiacomo Buechel ER, et al. Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease. J Cardiovasc Magn Reson 2013;15:51
DOI
|
27 |
Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med 2002;47:372-383
DOI
|
28 |
Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 2011;4:150-156
DOI
|